Phase 3 N=7 Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)
HTLV I Associated Myelopathy
Primary: Number of Patient With Lack of Objective Clinical Improvement — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=3 Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Acute Adult T-Cell Leukemia/Lymphoma · Adult T-Cell Leukemia/Lymphoma · Chronic Adult T-Cell Leukemia/Lymphoma
Primary: Incidence of Adverse Events of Nivolumab, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 3 Participants
N/A N=89,132 Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes
HSV-2 Infection · PreTerm Birth · Pregnancy Complications
Primary: Number of Participants With Preterm Delivery — 100; 83; 247; 5407 Participants
Phase 2 N=229 Combination Therapy for Chronic Hepatitis C Infection
Hepatitis C, Chronic
Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects
N/A N=52 A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Trachoma
Primary: The Proportion of Communities With C. Trachomatis Infection Prevalence of 1% or Below — 7; 4 community — p=>0.05
Phase 2 N=34 Anti-Tac for Treatment of Leukemia
HTLV-I Infection · T Cell Leukemia
Primary: Duration of Response — 114 Weeks
Phase 2 N=29 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
Acute T-Cell Leukemia-Lymphoma
Primary: Overall Response Rate — 52 percentage of participants
Phase 2 N=18 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
Adult T-Cell Leukemia (ATL)
Primary: Percentage of Participants With a Minimally Durable Clinical Response Rate — 80; 0; 60; 0 percentage of participants
Phase 2 N=4 Lenalidomide in HTLV-1 Adult T-Cell Leukemia
Adult T Cell Leukemia/Lymphoma
Primary: Response Rate (CR + Cru + PR)
N/A N=300 Supplemental Oxygen Reduces Surgical Infection
Wound Infection
Primary: Incisional Surgical Wound Infection — 22; 35 participants — p=0.04
N/A N=120 HIV And Parasitic Infection (HAPI) Study
HIV Coinfection
Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants
Phase 3 N=1,676 Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Covid19 · Non-specific Effects of Vaccines · Heterologous Immunity
Primary: Acute Infection — 424; 469; 212; 236 Events — p=< 0.05
Phase 3 N=95 Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection
Central Line-Associated Bloodstream Infection
Primary: Percentage of Therapeutic Failures (Early or Late Failure) in Children and Adolescents With CLABSI Receiving Standard Care Plus Ethanol Lock Therapy (ELT) vs. Standard…
Phase 2 N=15 Enhancement by Poly-ICLC During HIV-1 Infection
HIV-1 Infected Adults With Chronic HIV-1 Infection
Primary: Number Participants With Adverse Events — 11; 3 Participants
Phase 4 N=850 REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
HIV Infection
Primary: Cumulative Probability of Death or Unknown Vital Status by Week 24 — 5.2; 5.2 Cumulative probability per 100 persons — p=0.97